Shanahan Nancy A, Holick Pierz Kerri A, Masten Virginia L, Waeber Christian, Ansorge Mark, Gingrich Jay A, Geyer Mark A, Hen Rene, Dulawa Stephanie C
Committee on Neurobiology, University of Chicago, Chicago, Illinois 60637, USA.
Biol Psychiatry. 2009 Mar 1;65(5):401-8. doi: 10.1016/j.biopsych.2008.09.026. Epub 2008 Nov 14.
Obsessive-compulsive disorder (OCD) is characterized by intrusive thoughts, images, or impulses and/or repetitive stereotypical behavior. Obsessive-compulsive disorder patients exhibit reduced prepulse inhibition (PPI) and symptom exacerbation after challenge with 5-HT1B receptor agonists. Recently, gain-of-function alleles of the serotonin transporter (5-HTT) have been associated with OCD. We tested the hypothesis that reducing 5-HTT function chronically, either genetically or via serotonin reuptake inhibitor (SRI) treatment, attenuates PPI deficits and perseverative hyperlocomotion induced by 5-HT1B agonists in mice.
Mice received subchronic or chronic pretreatment with the SRI fluoxetine and acute treatment with RU24969 (5-HT1A/1B agonist) or 8-OH-DPAT (5-HT1A agonist) and were assessed for PPI, locomotor activity, and spatial patterns of locomotion. The same measures were evaluated in 5-HTT wild-type (WT), heterozygous (HT), and knockout (KO) mice after RU24969 treatment. The effects of WAY100635 (5-HTA antagonist) or GR127935 (5-HT1B/D antagonist) pretreatment on RU24969-induced effects were evaluated. Finally, 5-HT1B binding and functional coupling were assessed in 5-HTT-WT, -HT, and -KO mice, and normal fluoxetine-treated mice.
Chronic, but not subchronic, fluoxetine treatment prevented RU24969-induced PPI deficits and perseverative hyperlocomotion. These RU24969-induced effects were mediated via 5-HT1B and not 5-HT1A receptors. 5-HTT-KO mice showed no effects of RU24969, and 5-HTT-HT mice exhibited intermediate phenotypes. 5-HT1B binding and functional coupling were reduced in the globus pallidus and substantia nigra of 5-HTT-KO mice.
Our results demonstrate that chronic, but not subchronic, fluoxetine treatment and 5-HTT knockout robustly attenuate 5-HT1B agonist-induced PPI deficits and perseverative hyperlocomotion. These results may have implications for the etiology and treatment of OCD.
强迫症(OCD)的特征为侵入性思维、意象或冲动和/或重复性刻板行为。强迫症患者表现出前脉冲抑制(PPI)降低,且在5-HT1B受体激动剂激发后症状加重。最近,血清素转运体(5-HTT)的功能获得性等位基因与强迫症有关。我们检验了以下假设:长期通过基因手段或血清素再摄取抑制剂(SRI)治疗降低5-HTT功能,可减轻5-HT1B激动剂在小鼠中诱导的PPI缺陷和持续性运动亢进。
小鼠接受SRI氟西汀的亚慢性或慢性预处理,并接受RU24969(5-HT1A/1B激动剂)或8-OH-DPAT(5-HT1A激动剂)的急性治疗,随后评估其PPI、运动活性和运动空间模式。在RU24969治疗后,对5-HTT野生型(WT)、杂合子(HT)和敲除(KO)小鼠进行相同指标的评估。评估WAY100635(5-HTA拮抗剂)或GR127935(5-HT1B/D拮抗剂)预处理对RU24969诱导效应的影响。最后,在5-HTT-WT、-HT和-KO小鼠以及正常氟西汀治疗的小鼠中评估5-HT1B结合和功能偶联。
氟西汀的慢性而非亚慢性治疗可预防RU24969诱导的PPI缺陷和持续性运动亢进。这些RU24969诱导的效应是通过5-HT1B而非5-HT1A受体介导的。5-HTT-KO小鼠未表现出RU24969的效应,而5-HTT-HT小鼠表现出中间表型。5-HTT-KO小鼠苍白球和黑质中的5-HT1B结合和功能偶联减少。
我们的结果表明,氟西汀的慢性而非亚慢性治疗以及5-HTT敲除可有力减轻5-HT1B激动剂诱导的PPI缺陷和持续性运动亢进。这些结果可能对强迫症的病因学和治疗具有启示意义。